-
Mashup Score: 13
NHLBI PETAL Network ends Phase 3 sepsis trial early PETAL Network study found no significant difference in 90-day mortality rates, nor safety concerns, after providing patients with one of two common treatment strategies Enrollment in a National Institutes of Health-supported trial with 1,566 patients being treated for sepsis at 51 U.S. medical centers ended early due to a lack of…
Source: petalnet.orgCategories: Critical Care, Latest HeadlinesTweet
-
Mashup Score: 211ORCHID: Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease | PETAL Network - 4 year(s) ago
Effective therapies for COVID-19 are urgently needed. The PETAL Network is responding to the COVID-19 crisis and redirecting effort to develop and deploy COVID-19 trials. The first was the ORCHID Trial. Hydroxychloroquine is an antimicrobial agent with immunomodulatory and antiviral properties that has demonstrated in vitro activity against SARS-CoV-2, the virus that causes COVID-19. Preliminary…
Source: petalnet.orgCategories: Latest Headlines, PulmonologyTweet-
Dr. Wesley Self presenting the ORCHID Trial: a blinded, multicenter, placebo-controlled randomized clinical trial of #Hydroxychloroquine for #COVID19. Stopped mid-June after 479 patients due to lack of benefit. #CHEST2020 https://t.co/L4CuzAWLdz
-
#CLOVERS stopped early for no difference between early vasopressors vs fluids in septic shock (max fluid 1 L-3 L at enrollment). FINALLY some prospective data showing 30 mL/kg is NOT necessary for all. Can’t wait for the full pub. @nih_nhlbi #PharmICU https://t.co/ivIIyTkC8J